 Methylphenidate
"Methylphenidate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE.
| Descriptor ID |
D008774
|
| MeSH Number(s) |
D02.241.223.601.600 D03.383.621.460
|
| Concept/Terms |
Focalin- Focalin
- Novartis Pharmaceutical Brand of Dexmethylphenidate Hydrochloride
Metadate- Metadate
- Equasym
- Celltech Brand of Methylphenidate Hydrochloride
Ritalin- Ritalin
- Novartis Brand 1 of Methylphenidate Hydrochloride
- Ritaline
- Cephalon Brand of Methylphenidate Hydrochloride
Ritalin-SR- Ritalin-SR
- Ritalin SR
- Novartis Brand 2 of Methylphenidate Hydrochloride
Methylin- Methylin
- Mallinckrodt Brand of Methylphenidate Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Methylphenidate".
Below are MeSH descriptors whose meaning is more specific than "Methylphenidate".
This graph shows the total number of publications written about "Methylphenidate" by people in UAMS Profiles by year, and whether "Methylphenidate" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 1 | 1 | 2 | | 2023 | 3 | 0 | 3 | | 2022 | 1 | 0 | 1 | | 2021 | 5 | 0 | 5 | | 2020 | 7 | 0 | 7 | | 2019 | 1 | 0 | 1 | | 2018 | 4 | 0 | 4 | | 2017 | 1 | 0 | 1 | | 2016 | 2 | 1 | 3 | | 2014 | 1 | 1 | 2 | | 2012 | 2 | 0 | 2 | | 2011 | 3 | 0 | 3 | | 2010 | 1 | 1 | 2 | | 2007 | 2 | 1 | 3 | | 2006 | 0 | 1 | 1 | | 2005 | 2 | 0 | 2 | | 2004 | 2 | 0 | 2 | | 2003 | 0 | 1 | 1 | | 2002 | 1 | 1 | 2 | | 1998 | 0 | 1 | 1 | | 1991 | 0 | 1 | 1 | | 1990 | 1 | 0 | 1 | | 1989 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Methylphenidate" by people in Profiles over the past ten years.
-
Hiranita T, Li SM, Katz JL. Effects of Dual Inhibition at Dopamine Transporter and s Receptors in the Discriminative-Stimulus Effects of Cocaine in Male Rats. J Pharmacol Exp Ther. 2024 Oct 18; 391(2):308-316.
-
Zeng L, Perin J, Gross AL, Shade D, Lanct?t KL, Lerner AJ, Mintzer JE, Brawman-Mintzer O, Padala PR, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Herrmann N, Rosenberg PB. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial). Int J Geriatr Psychiatry. 2024 Jun; 39(6):e6108.
-
Lanct?t KL, Rivet L, Tumati S, Perin J, Sankhe K, Vieira D, Mintzer J, Rosenberg PB, Shade D, Lerner AJ, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey AI, Padala KP, Herrmann N. Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial. Am J Geriatr Psychiatry. 2023 12; 31(12):1077-1087.
-
Lanct?t KL, Chen C, Mah E, Kiss A, Li A, Shade D, Scherer RW, Vieira D, Coulibaly H, Rosenberg PB, Lerner AJ, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Burke WJ, Mintzer J, Herrmann N. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). Int Psychogeriatr. 2023 11; 35(11):664-672.
-
Zhang X, Berridge MS, Apana SM, Slikker W, Paule MG, Talpos J. Discontinuation of methylphenidate after long-term exposure in nonhuman primates. Neurotoxicol Teratol. 2023 May-Jun; 97:107173.
-
Liachenko S, Chelonis J, Paule MG, Li M, Sadovova N, Talpos JC. The effects of long-term methylphenidate administration and withdrawal on progressive ratio responding and T2 MRI in the male rhesus monkey. Neurotoxicol Teratol. 2022 Sep-Oct; 93:107119.
-
Mintzer J, Lanct?t KL, Scherer RW, Rosenberg PB, Herrmann N, van Dyck CH, Padala PR, Brawman-Mintzer O, Porsteinsson AP, Lerner AJ, Craft S, Levey AI, Burke W, Perin J, Shade D. Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. JAMA Neurol. 2021 11 01; 78(11):1324-1332.
-
Weiss MD, Surman C, Khullar A, Owens J, He E, Cataldo M, Donnelly G. Effect of a Multilayer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Trial Followed by a 6-Month Open-Label Follow-Up. J Child Adolesc Psychopharmacol. 2021 11; 31(9):623-630.
-
Weiss MD, Cutler AJ, Kollins SH, Donnelly GAE. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension. J Child Adolesc Psychopharmacol. 2021 11; 31(9):610-622.
-
Zhang X, Talpos J, Berridge MS, Apana SM, Slikker W, Wang C, Paule MG. MicroPET/CT assessment of neurochemical effects in the brain after long-term methylphenidate treatment in nonhuman primates. Neurotoxicol Teratol. 2021 Sep-Oct; 87:107017.
-
Weiss MD, Surman C, Khullar A, He E, Cataldo M, Donnelly G. Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension. CNS Drugs. 2021 06; 35(6):667-679.
-
Addicott MA, Pearson JM, Schechter JC, Sapyta JJ, Weiss MD, Kollins SH. Attention-deficit/hyperactivity disorder and the explore/exploit trade-off. Neuropsychopharmacology. 2021 02; 46(3):614-621.
-
Lanct?t KL, Scherer RW, Li A, Vieira D, Coulibaly H, Rosenberg PB, Herrmann N, Lerner AJ, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Burke WJ, Mintzer JE. Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments. Am J Geriatr Psychiatry. 2021 01; 29(1):81-89.
-
Horne VE, Bielamowicz K, Nguyen J, Hilsenbeck S, Lindsay H, Sonabend R, Wood AC, Okcu F, Sisley S. Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. Pediatr Blood Cancer. 2020 07; 67(7):e28379.
-
van Dyck CH, Arnsten AFT, Padala PR, Brawman-Mintzer O, Lerner AJ, Porsteinsson AP, Scherer RW, Levey AI, Herrmann N, Jamil N, Mintzer JE, Lanct?t KL, Rosenberg PB. Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. Am J Geriatr Psychiatry. 2021 01; 29(1):51-62.
-
Mereu M, Hiranita T, Jordan CJ, Chun LE, Lopez JP, Coggiano MA, Quarterman JC, Bi GH, Keighron JD, Xi ZX, Newman AH, Katz JL, Tanda G. Modafinil potentiates cocaine self-administration by a dopamine-independent mechanism: possible involvement of gap junctions. Neuropsychopharmacology. 2020 08; 45(9):1518-1526.
-
Padala PR, Padala KP, Samant RS, James GA. Improvement of neuronal integrity with methylphenidate treatment for apathy in Alzheimer's disease. Int Psychogeriatr. 2020 04; 32(4):539-540.
-
Weiss MD, Childress AC, Donnelly GAE. Efficacy and Safety of PRC-063, Extended-Release Multilayer Methylphenidate in Adults with ADHD Including 6-Month Open-Label Extension. J Atten Disord. 2021 08; 25(10):1417-1428.
-
Addicott MA, Schechter JC, Sapyta JJ, Selig JP, Kollins SH, Weiss MD. Methylphenidate increases willingness to perform effort in adults with ADHD. Pharmacol Biochem Behav. 2019 08; 183:14-21.
-
Padala PR, Dennis RA, Padala KP. Addressing Possible Effects of Sleep Apnea in a Study of Methylphenidate for Apathy in Alzheimer's Disease: Response to Kolla and Mansukhani. Am J Psychiatry. 2018 08 01; 175(8):792-793.
-
Weiss M, Childress A, Mattingly G, Nordbrock E, Kupper RJ, Adjei AL. Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial. J Child Adolesc Psychopharmacol. 2018 10; 28(8):521-529.
-
Froehlich TE, Becker SP, Nick TG, Brinkman WB, Stein MA, Peugh J, Epstein JN. Sluggish Cognitive Tempo as a Possible Predictor of Methylphenidate Response in Children With ADHD: A Randomized Controlled Trial. J Clin Psychiatry. 2018 Mar/Apr; 79(2).
-
Scherer RW, Drye L, Mintzer J, Lanct?t K, Rosenberg P, Herrmann N, Padala P, Brawman-Mintzer O, Burke W, Craft S, Lerner AJ, Levey A, Porsteinsson A, van Dyck CH. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018 Jan 18; 19(1):46.
-
Sweitzer MM, Kollins SH, Kozink RV, Hallyburton M, English J, Addicott MA, Oliver JA, McClernon FJ. ADHD, Smoking Withdrawal, and Inhibitory Control: Results of a Neuroimaging Study with Methylphenidate Challenge. Neuropsychopharmacology. 2018 03; 43(4):851-858.
-
Padala PR, Padala KP, Lensing SY, Ramirez D, Monga V, Bopp MM, Roberson PK, Dennis RA, Petty F, Sullivan DH, Burke WJ. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2018 02 01; 175(2):159-168.
-
Dougherty DM, Olvera RL, Acheson A, Hill-Kapturczak N, Ryan SR, Mathias CW. Acute effects of methylphenidate on impulsivity and attentional behavior among adolescents comorbid for ADHD and conduct disorder. J Adolesc. 2016 Dec; 53:222-230.
-
Zhang X, Newport GD, Callicott R, Liu S, Thompson J, Berridge MS, Apana SM, Slikker W, Wang C, Paule MG. MicroPET/CT assessment of FDG uptake in brain after long-term methylphenidate treatment in nonhuman primates. Neurotoxicol Teratol. 2016 Jul-Aug; 56:68-74.
-
Freyberg Z, Sonders MS, Aguilar JI, Hiranita T, Karam CS, Flores J, Pizzo AB, Zhang Y, Farino ZJ, Chen A, Martin CA, Kopajtic TA, Fei H, Hu G, Lin YY, Mosharov EV, McCabe BD, Freyberg R, Wimalasena K, Hsin LW, Sames D, Krantz DE, Katz JL, Sulzer D, Javitch JA. Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain. Nat Commun. 2016 Feb 16; 7:10652.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|